Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
BARRX Medical Inc., a leader in the development of minimally invasive medical devices designed to remove precancerous tissue from within the gastrointestinal tract, reported today that the Society of American Gastrointestinal and Endoscopic Surgeons has issued a new practice guideline for the surgical treatment of gastroesophageal reflux disease. Left untreated, reflux of stomach contents such as acid and bile into the esophagus in GERD patients often leads to injury and chronic inflammation of the lining of the esophagus.
Patients who received radiofrequency ablation for varicose veins reported less post-procedural pain than those treated with endovenous laser ablation. However, both groups reported the same clinical and quality of life improvements at six weeks.
Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
Results from two major multi-center clinical trials presented at the Digestive Disease Week in New Orleans independently confirmed that the effects of endoscopic radiofrequency ablation (RFA) for eradicating a pre-cancerous condition of the esophagus called Barrett's esophagus are durable in the long-term. In a plenary scientific presentation titled "Endoscopic Radiofrequency Ablation for Barrett's Esophagus: Five-year Durability Outcomes from a Prospective Multi-Center Trial," patients with Barrett's esophagus were treated with endoscopic RFA using the HALO system.
Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.
Boston Scientific Corporation today announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its SpyGlass Direct Visualization System, Radial Jaw 4 Biopsy Forceps and WallFlex Duodenal Stent will be presented at Digestive Disease Week, May 1 – 5 in New Orleans.
Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.
Stryker's Interventional Spine business unit today announced the release of its iVAS inflatable vertebral augmentation system, a minimally invasive device cleared for use in treating vertebral compression fractures.
Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.
A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population.
A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).
An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the surrounding healthy liver, contributes to prolongation of their life by nearly three years, note researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
Over the past 40 years, more than 2,400 patents and patent applications-pioneering modern medicine with the devices and drugs that advance minimally invasive treatments-have been filed by members of the Society of Interventional Radiology.
According to Millennium Research Group, the global authority on medical technology market intelligence, the recent launch of irrigated-tip catheters into the Japanese market will drive the ablation catheter market by a compound annual growth rate of approximately 15% through 2014.
Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.
Acculis Limited today announced the regulatory clearance of its revolutionary new device for destroying unwanted tissues, such as liver tumours. The clearance under the European CE Mark system allows the company to begin deliveries for treating patients throughout Europe and elsewhere where the CE Mark system is recognised. The device is a single high power high frequency 2.45GHz microwave needle that burns a 5cm sphere of tissue in just 5 minutes which is between 3 to 10 times faster than old school radiofrequency based systems or lower frequency 915MHz microwave systems.
Early tumor formation in Barrett's esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.
Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.